NASDAQ:GTBP

GT Biopharma (GTBP) Stock Forecast, Price & News

$0.29

+0.04 (+16.16%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.25
▼
$0.30
50-Day Range: $0.23
▼
$0.58
52-Week Range: $0.18
▼
$3.29

Volume: 763,634 shs
Average Volume: 239,060 shs
Market Capitalization: $10.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

GT Biopharma MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 1,117.0% Upside
$3.50 Price Target
Short Interest: Healthy
0.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$50,000 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

213th out of 983 stocks

Pharmaceutical Preparations Industry

95th out of 486 stocks

3.2

Analyst's Opinion

Consensus Rating
GT Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, GT Biopharma has a forecasted upside of 1,117.0% from its current price of $0.29.
Amount of Analyst Coverage
GT Biopharma has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.40% of the float of GT Biopharma has been sold short.
Short Interest Ratio / Days to Cover
GT Biopharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GT Biopharma has recently decreased by 12.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
GT Biopharma does not currently pay a dividend.
Dividend Growth
GT Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GTBP.

3.1

News and Social Media Coverage

News Sentiment
GT Biopharma has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for GT Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for GTBP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GT Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.10% of the stock of GT Biopharma is held by insiders.
Percentage Held by Institutions
Only 7.62% of the stock of GT Biopharma is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of GT Biopharma is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GT Biopharma is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GT Biopharma has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GT Biopharma (NASDAQ:GTBP) Stock

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Stock News Headlines

June 2, 2023 | msn.com

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now

May 19, 2023 | msn.com

All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin

$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.

May 18, 2023 | msn.com

HC Wainwright & Co. Reiterates GT Biopharma (GTBP) Buy Recommendation

May 17, 2023 | msn.com

EF Hutton Reiterates GT Biopharma (GTBP) Hold Recommendation

May 16, 2023 | finanznachrichten.de

GT Biopharma, Inc.: GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA), GT Biopharma (GTBP) and Spruce Biosciences (SPRB)

May 15, 2023 | finance.yahoo.com

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin

April 14, 2023 | americanbankingnews.com

GT Biopharma, Inc. (OTCMKTS:GTBP) CEO Purchases $25,000.00 in Stock

April 12, 2023 | americanbankingnews.com

Manu Ohri Purchases 50,000 Shares of GT Biopharma, Inc. (OTCMKTS:GTBP) Stock

April 5, 2023 | americanbankingnews.com

GT Biopharma, Inc. Forecasted to Post Q1 2023 Earnings of ($0.16) Per Share (OTCMKTS:GTBP)

April 3, 2023 | americanbankingnews.com

GT Biopharma (OTCMKTS:GTBP) Given Buy Rating at HC Wainwright

April 3, 2023 | markets.businessinsider.com

GT Biopharma (GTBP) Gets a Buy from H.C. Wainwright

April 2, 2023 | benzinga.com

GT Biopharma Inc Up 20.52% To $0.56 After Earnings Miss

April 1, 2023 | finanznachrichten.de

GT Biopharma, Inc.: GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

April 1, 2023 | americanbankingnews.com

GT Biopharma's (GTBP) Hold Rating Reaffirmed at EF Hutton Acquisition Co. I

April 1, 2023 | benzinga.com

GT Biopharma Stock (NASDAQ:GTBP), Dividends

March 31, 2023 | markets.businessinsider.com

EF Hutton Keeps Their Hold Rating on GT Biopharma (GTBP)

March 30, 2023 | finance.yahoo.com

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 26, 2023 | americanbankingnews.com

GT Biopharma (GTBP) Scheduled to Post Earnings on Monday

February 24, 2023 | finance.yahoo.com

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

February 2, 2023 | finance.yahoo.com

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

December 30, 2022 | msn.com

GT Biopharma slips on $6.5M stock offering

December 14, 2022 | finance.yahoo.com

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

December 12, 2022 | msn.com

Fate Therapeutics hits 52-week low after preclinical data on leukemia treatment

December 12, 2022 | finance.yahoo.com

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

See More Headlines

GTBP Price History

30 days | 90 days | 365 days | Advanced Chart

GTBP Company Calendar

Last Earnings: 4/15/2021
Today: 6/03/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GTBP
Previous Symbol: OTCMKTS:OXISD
CUSIP: N/A
CIK: 109657
Web: www.gtbiopharma.com
Phone: (415) 919-4040
Fax: N/A
Employees: 8
Year Founded: 1965

Price Target and Rating

Average Stock Price Forecast: $3.50
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +1,117.0%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,880,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -132.40%
Return on Assets: -90.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.89
Quick Ratio: 4.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 37,360,000
Free Float: 35,082,000
Market Cap: $10.74 million
Optionable: Not Optionable
Beta: 0.86

Social Links

Key Executives

Michael Breen
Executive Chairman & Chief Executive Officer

Manu Ohri
Chief Financial Officer

Jeffrey Miller
Chief Scientific & Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GTBP Stock - Frequently Asked Questions

Should I buy or sell GT Biopharma stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GTBP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GTBP, but not buy additional shares or sell existing shares.
View GTBP analyst ratings or view top-rated stocks.
What is GT Biopharma's stock price forecast for 2023?: 3 equities research analysts have issued 1 year price targets for GT Biopharma's shares. Their GTBP share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 1,117.0% from the stock's current price.
View analysts price targets for GTBP or view top-rated stocks among Wall Street analysts.
How have GTBP shares performed in 2023?: GT Biopharma's stock was trading at $0.8857 on January 1st, 2023. Since then, GTBP shares have decreased by 67.5% and is now trading at $0.2876.
View the best growth stocks for 2023 here.
Are investors shorting GT Biopharma?: GT Biopharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 141,400 shares, a decrease of 12.8% from the April 30th total of 162,200 shares. Based on an average daily trading volume, of 149,500 shares, the short-interest ratio is presently 0.9 days. Currently, 0.4% of the shares of the company are short sold.
View GT Biopharma's Short Interest.
When is GT Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GTBP earnings forecast.
How were GT Biopharma's earnings last quarter?: GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Thursday, April, 15th. The company reported ($3.39) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $3.35.

What is GT Biopharma's stock symbol?: GT Biopharma trades on the NASDAQ under the ticker symbol "GTBP."
Who are GT Biopharma's major shareholders?: GT Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.89%). Insiders that own company stock include Manu Ohri, Michael Martin Breen and Steven W Weldon.
View institutional ownership trends.
How do I buy shares of GT Biopharma?: Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GT Biopharma's stock price today?: One share of GTBP stock can currently be purchased for approximately $0.29.
How much money does GT Biopharma make?: GT Biopharma (NASDAQ:GTBP) has a market capitalization of $10.74 million. The company earns $-20,880,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.
How can I contact GT Biopharma?: GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The official website for the company is www.gtbiopharma.com. The company can be reached via phone at (415) 919-4040 or via email at info@oxis.com.

This page (NASDAQ:GTBP) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial